Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | USP1 | O94782 | 13/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 13/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497382 | 0.82 | MAPK8 (0.53) | MAPK8USP1WDR48 | |
| SCHEMBL3496138 | 0.77 | PARP1 (0.47) | MAPK8USP1WDR48TSHRHSD17B10 | |
| SCHEMBL3495003 | 0.74 | RPS6KA5 (0.33) | — | |
| SCHEMBL17895298 | 0.69 | IKBKB (0.42) | CYP1A2CYP2D6CYP2C9CYP2C19PKM | |
| SCHEMBL3498276 | 0.69 | KDM4E (0.42) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL12886763 | 0.68 | KDM4E (0.48) | USP1WDR48CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL124220 | 0.67 | IKBKB (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL119071 | 0.67 | HTR3E (0.39) | MAPK8CYP3A4 | |
| SCHEMBL31377522 | 0.67 | MAPK8 (0.40) | MAPK8PKM | |
| SCHEMBL120846 | 0.66 | MAPK8 (0.54) | MAPK8HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| EP-2155750-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | Mutabilis SA (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | MAPK8 4234/4885USP1 787/4885WDR48 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.